Point72 Asset Management
IKT icon

Point72 Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Point72 Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,383
Closed -$67.8K – 4276
2026
Q1 		$67.8K Buy
+40,383
New +$71.7K ﹤0.01% 3644

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management's IKT Position: Q2 2026 in Review

Point72 Asset Management sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 40,383 shares — an estimated $67.8K sold.

Point72 Asset Management first reported a position in IKT in Q1 2026 and held it in 1 quarter. The position peaked at $67.8K in Q1 2026. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Point72 Asset Management reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 40,383 Inhibikase Therapeutics shares in Q2 2026, an estimated $67.8K.
  • Point72 Asset Management first reported a position in Inhibikase Therapeutics in Q1 2026 and held it in 1 quarter.
  • Point72 Asset Management's Inhibikase Therapeutics position peaked at $67.8K in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.